Flunarizine is not approved for tension-type headache prophylaxis. Some clinicians may prescribe it off-label for this purpose, but robust evidence is lacking. Use should be guided by a specialist.
In the UK, the 5 mg tablet is typically white, round, and imprinted with “FLU 5”. The 10 mg tablet is usually white, round, and marked “FLU 10”. Inactive ingredients may include lactose, starch, and magnesium stearate.
Flunarizine is not a controlled substance and is not screened for in standard occupational or anti-doping drug tests. However, athletes should verify with their governing body if any restrictions exist.
Initial therapy often causes drowsiness; patients should assess their own response before operating vehicles. Once the dose is stabilised and side effects have resolved, most individuals can drive safely.
Combination therapy is sometimes used (e.g., with beta-blockers or topiramate) but increases the risk of adverse effects. Any combination should be prescribed and monitored by a neurologist.
Clinical improvement usually appears after 4-6 weeks of consistent dosing, though some patients report benefit earlier. Patience and adherence are important for optimal results.
There are no strict dietary restrictions, but taking the medication with a light snack can minimise stomach upset. Avoid excessive alcohol, which can amplify sedation.
Weight gain is a known side effect. Discuss lifestyle modifications with your healthcare provider; dose reduction or switching to an alternative preventive may be considered.
Flunarizine can exacerbate depressive symptoms and has been associated with rare cases of suicidal ideation. Patients with a history of mood disorders should be evaluated carefully, and mood should be monitored throughout therapy.
Yes, but clinicians usually start at the low 5 mg dose and monitor for increased sedation, falls, and weight gain, as older adults may be more sensitive to these effects.
Flunarizine is a calcium-channel-blocking agent that belongs to the neurology therapeutic class. It is supplied as oral pills in strengths of 5 mg and 10 mg. In the United Kingdom Flunarizine is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is commonly prescribed for the prevention of migraine attacks and for certain types of vertigo.
Flunarizine blocks voltage-gated L-type calcium channels in neuronal membranes. By reducing calcium influx, it dampens neuronal excitability and stabilises the firing patterns that can trigger migraine or vestibular disturbances. The compound also has antihistamine and mild antidopaminergic properties, which may contribute to its efficacy in vestibular disorders. After oral ingestion, the drug is well absorbed, reaches peak plasma concentrations within 2-4 hours, and has a long elimination half-life of approximately 18 days, allowing once-daily dosing.
These indications are based on UK marketing authorisation and are reflected in the product’s Summary of Product Characteristics (SmPC).
This article provides educational information about Flunarizine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
